A feasibility and tolerability study of lithium in Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 23, Issue 7, 2008, Pages 704-711

  Macdonald, Alastair ^a   Briggs, Kate ^a   Poppe, Michaela ^a   Higgins, Andrea ^a   Velayudhan, Latha ^a   Lovestone, Simon ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Disease modifying; GSK 3; Lithium; Trial

Indexed keywords

LITHIUM;

AGED; ALZHEIMER DISEASE; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; HUMAN; LOW DRUG DOSE; LUNG EDEMA; MALE; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA; RATING SCALE; TREMOR;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEASIBILITY STUDIES; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM COMPOUNDS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PATIENT SELECTION; PSYCHIATRIC STATUS RATING SCALES;

EID: 48249096759     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.1964     Document Type: Article

References (43)

1. Aghdam SY, Barger SW. 2007. Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: lessons from lithium. Curr Alzheimer Res 4(1): 21-31.
2. Bearden CE, Thompson PM, Dalwani M, et al. 2007a. Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol Psychiatry 62(1): 7-16.
3. Bearden CE, Thompson PM, Dutton RA, et al. 2007b. Three-dimensional mapping of hippocampal anatomy in unmedicated and lithium-treated patients with bipolar disorder. Neuropsychopharmacol, 2007 Aug 8; [Epub ahead of print]
4. Bhat RV, Budd Haeberlein SL, Avila J. 2004b. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 89(6): 1313-1317.
5. Bhat RV, Budd Haeberlein SL, Avila J. 2004a. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 89(6): 1313-1317.
6. Chuang DM, Manji HK. 2007. In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked? Biol Psychiatry 62(1): 4-6.
7. Cummings JL, Mega M, Gray K, et al. 1994. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44(12): 2308-2314.
8. De Ferrari GV, Chacon MA, Barria MI, et al. 2003. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry 8(2): 195-208.
9. Dunn N, Holmes C, Mullee M. 2005. Does lithium therapy protect against the onset of DEMENTIA? Alzheimer Dis Assoc Disord 19(1): 20-22.
10. Ellul J, Archer N, Foy CM, et al. 2007. The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration. J Neurol Neurosurg Psychiatry 78(3): 233-239.
11. Ferri CP, Prince M, Brayne C, et al. 2005. Global prevalence of dementia: a Delphi consensus study. Lancet 366(9503): 2112-2117.
12. Folstein MF, Folstein SE, McHugh PR. 1975. 'Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
13. Fountoulakis KN, Vieta E, Bouras C, et al. 2007. A systematic review of existing data on long-term lithium therapy: neuroprotective or neurotoxic? Int J Neuropsychopharmacol 1-19. [Epub ahead of print]
14. Ghribi O, Prammonjago P, Herman MM, et al. 2003. Abeta(1-42)-induced JNK and ERK activation in rabbit hippocampus is differentially regulated by lithium but is not involved in the phosphorylation of tau. Brain Res Mol Brain Res 119(2): 201-206.
15. Haddad P, Wieck A, Yarrow M, Denham P. 1999. The Lithium Side Effects Rating Scale (LISERS); development of a self-rating instrument. Eur Neuropsychopharmacol 9(s5): 231-232.
16. Hernandez F, Borrell J, Guaza C, et al. 2002. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem 83(6): 1529-1533.
17. Hindmarch I, Lehfeld H, De Jongh P, Erzigkeit H. 1998. The Bayer Activities of Daily Living Scale (B-ABL). Dementia 9 (Suppl. 2): 20-26.
18. Hooper C, Markevich V, Plattner F, et al. 2007. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci 25(1): 81-86.
19. Huang He, Klein PS. 2006. Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease. Curr Drug Targets 7(11): 1389-1397.
20. Hye A, Kerr F, Archer N, et al. 2005. Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci Lett 373(1): 1-4.
21. Hye A, Lynham S, Thambisetty M, et al. 2006. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129 (Pt 11): 3042-3050.
22. Jackson GR, Wiedau-Pazos M, Sang T-K, et al. 2002. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary tangles in Drosophila. Neuron 34: 509-519.
23. Jope RS. 2003. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 24(9): 441-443.
24. Leroy K, Menu R, Conreur JL, et al. 2000. The function of the microtubule-associated protein tau is variably modulated by graded changes in glycogen synthase kinase- 3β activity. FEBS Lett 465: 34-38.
25. Lucas JJ, Hernandez F, Gomez-Ramos P, et al. 2001. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20(1-2): 27-39.
26. Mazanetz MP, Fischer PM. 2007. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 6(6): 464-479.
27. Moore GJ, Bebchuk JM, Wilds IB, et al. 2000. Lithium-induced increase in human brain grey matter. Lancet 356(9237): 1241-1242.
28. Mudher A, Lovestone S. 2002. Alzheimer's disease - do tauists and baptists finally shake hands? Trends Neurosci 25(1): 22-26.
29. Mudher A, Shepherd D, Newman TA, et al. 2004. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry 9(5): 522-530.
30. Mukhopadhyay D, Gokulkrishnan L, Mohanaruban K. 2001. Lithium-induced nephrogenic diabetes insipidus in older people. Age Ageing 30(4): 347-350.
31. Noble W, Planel E, Zehr C, et al. 2005. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 102(19): 6990-6995.
32. Nunes PV, Forlenza OV, Gattaz WF. 2007. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 190: 359-360.
33. Oakley PW, Dawson AH, Whyte IM. 2000. Lithium: thyroid effects and altered renal handling. J Toxicol Clin Toxicol 38(3): 333-337.
34. Oudit GY, Korley V, Backx PH, Dorian P. 2007. Lithium-induced sinus node disease at therapeutic concentrations: linking lithium-induced blockade of sodium channels to impaired pacemaker activity. Can J Cardiol 23(3): 229-232.
35. Pei JJ, Braak E, Braak H, et al. 1999. Distribution of active glycogen synthase kinase 3β (GSK- 3β) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58: 1010-1019.
36. Reisberg B, Ferris SH, De Leon MJ, Crook T. 1982. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 139: 1136-1139.
37. Rockenstein E, Torrance M, Adame A, et al. 2007. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 27(8): 1981-1991.
38. Rosen WG, Mohs RC, Davis KL. 1984. A new rating scale for Alzheimer's disease. Am J Psychiatry 141(11): 1356-1364.
39. Shulman KI, Sykora K, Gill S, et al. 2005. Incidence of delirium in older adults newly prescribed lithium or valproate: a population-based cohort study. J Clin Psychiatry 66(4): 424-427.
40. Terao T, Nakano H, Inoue Y, Okamoto T, Nakamura J, Iwata N. 2006. Lithium and dementia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 30(6): 1125-1128.
41. Tsai SY, Lee CH, Kuo CJ, Chen CC. 2005. A retrospective analysis of risk and protective factors for natural death in bipolar disorder. J Clin Psychiatry 66(12): 1586-1591.
42. Vellas B, Andrieu S, Sampaio C, Wilcock G. 2007. Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 6(1): 56-62.
43. Wolf ME, Moffat M, Mosnaim J, Dempsey S. 1997. Lithium therapy, hypercalcemia, and hyperparathyroidism. Am J Ther 4(9-10): 323-325.